Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ROBO4 short hairpin RNA (shRNA) is an experimental RNA interference (RNAi) therapeutic candidate designed to silence the expression of Roundabout homolog 4 (ROBO4). While ROBO4 is traditionally recognized for its role in endothelial cells and angiogenesis, recent research has identified its expression in epithelial breast cancer cells, particularly in basal-like tumors. By targeting ROBO4, this shRNA reduces the population of hybrid epithelial-mesenchymal stem-like cells, thereby inhibiting tumor growth, colony formation, and cellular plasticity. Preclinical studies using patient-derived xenograft (PDX) models have demonstrated that both constitutive and inducible knockdown of ROBO4 can significantly reduce tumorigenesis and halt the growth of established tumors. The cell-surface location of ROBO4 makes it an attractive target for potential therapeutic applications in breast cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ROBO4 short hairpin RNA.